Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 12/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113592 | 0.81 | GSK3B (0.54) | GSK3BGRM5VNN1ELANE | |
| SCHEMBL30460400 | 0.81 | GSK3B (0.54) | GSK3BGRM5VNN1ELANE | |
| SCHEMBL30460427 | 0.80 | GSK3B (0.52) | GSK3BGRM5VNN1ELANE | |
| SCHEMBL25310631 | 0.80 | GSK3B (0.52) | GSK3BGRM5VNN1ELANE | |
| SCHEMBL30460566 | 0.79 | GSK3B (0.51) | GSK3BGRM5VNN1ALDH1A1HPGD | |
| SCHEMBL25260579 | 0.79 | GSK3B (0.51) | GSK3BGRM5VNN1ALDH1A1HPGD | |
| SCHEMBL25310174 | 0.75 | GSK3B (0.50) | GSK3BGRM5VNN1 | |
| SCHEMBL30460418 | 0.75 | GSK3B (0.50) | GSK3BGRM5VNN1 | |
| SCHEMBL25310003 | 0.73 | GSK3B (0.51) | GSK3BGRM5VNN1SMN1; SMN2ELANE | |
| SCHEMBL310975 | 0.73 | GSK3B (0.51) | GSK3BGRM5VNN1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1910178-B | Thiazole derivatives as A2B antagonists | NOVARTIS AG | 2010-06-02 | — | — | CN | disclosed |
| US-20090233938-A1 | Thiazole derivatives as a2b antagonists | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1709036-B1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | NOVARTIS AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| CN-1910178-A | Thiazole derivatives as A2B antagonists | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| EP-1709036-A1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070926-A1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233938-A1 | Thiazole derivatives as a2b antagonists | ADORA2B, ADRA2B, AGTR2 | GSK3B 4388/4885GRM5 1915/4885VNN1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.